## **ZP3022**

Cat. No.:	HY-P10341
Molecular Formula:	C <sub>199</sub> H <sub>294</sub> N <sub>48</sub> O <sub>61</sub> S
Molecular Weight:	4366.81
Sequence:	His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Le u-Phe-Ile-Glu-Trp-Leu-Lys-Asn-(8Ado)-(8Ado)-Tyr-Gly-Trp-Leu-Asp-Phe-NH2 8Ado: 8-a mino-3,6-dioxaoctanoic acid
Sequence Shortening:	HGEGTFTSDLSKQMEEEAVRLFIEWLKN-(8Ado)-(8Ado)-YGWLDF-NH2 8Ado: 8-amino-3,6 -dioxaoctanoic acid
Target:	GCGR
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of

## **BIOLOGICAL ACTIVITY**

ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin, which has the ability to continuously improve Description glycemic control. Meanwhile, ZP3022 can effectively increase the mass of  $\beta$ -cells, promote  $\beta$ -cell proliferation, and enhance the average islet mass. ZP3022 can be used in research for anti-diabetic treatments<sup>[1]</sup>.

## REFERENCES

[1]. Dalbøge LS, et al. The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice. J Pharmacol Exp Ther. 2014;350(2):353-360.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet

